| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/28/2013 | US20130079344 Ophthalmologic irrigation solutions and method |
| 03/28/2013 | US20130079338 Selective NR2B Antagonists |
| 03/28/2013 | US20130079337 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| 03/28/2013 | US20130079336 Treatment of Prolonged Status Epilepticus |
| 03/28/2013 | US20130079335 Benzotriazolodiazepine Compounds Inhibitors Of Bromodomains |
| 03/28/2013 | US20130079334 Compositions for Delivery of Insoluble Agents |
| 03/28/2013 | US20130079333 Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
| 03/28/2013 | US20130079332 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| 03/28/2013 | US20130079328 Compositions and methods for modulating the wnt signaling pathway |
| 03/28/2013 | US20130079326 N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
| 03/28/2013 | US20130079324 Pyrrolopyrimidine and purine derivatives |
| 03/28/2013 | US20130079321 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| 03/28/2013 | US20130079318 Beta-lactamase inhibitory compounds |
| 03/28/2013 | US20130079317 Methods for treatment of diseases |
| 03/28/2013 | US20130079315 Ophthalmic Gel Compositions |
| 03/28/2013 | US20130079314 Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
| 03/28/2013 | US20130079313 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 03/28/2013 | US20130079312 Method of Treating Hair Loss Due to Systemic Chemotherapy |
| 03/28/2013 | US20130079311 Compositions and kits for compounding pharmaceuticals |
| 03/28/2013 | US20130079310 Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels |
| 03/28/2013 | US20130079309 Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists |
| 03/28/2013 | US20130079307 Medicine, food and drink or feed containing sphingomyelin |
| 03/28/2013 | US20130079305 3-substituted vinylboronates and uses thereof |
| 03/28/2013 | US20130079304 Pharmaceutical Compositions for the Treatment of Fungal Infections |
| 03/28/2013 | US20130079301 Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion |
| 03/28/2013 | US20130079299 Arthritis Therapeutic Agent |
| 03/28/2013 | US20130079297 Kinase protein binding inhibitors |
| 03/28/2013 | US20130079294 Extracts and isolated flavonoids from euphorbia cuneata useful as anti-ulcer agents |
| 03/28/2013 | US20130079290 S1p antagonists as adjunct ocular hypotensives |
| 03/28/2013 | US20130079284 Treatment of t-cell mediated diseases |
| 03/28/2013 | US20130079271 Reversed biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| 03/28/2013 | US20130078650 Identifying material from a breast duct |
| 03/28/2013 | US20130078320 Composition for treating hearing loss |
| 03/28/2013 | US20130078318 Combination dosage forms and therapies for supporting bone health |
| 03/28/2013 | US20130078317 Zinc-containing compositions for the treatment of diseases, illnesses and syndromes associated with exposure to pore forming toxins |
| 03/28/2013 | US20130078309 Oral particulate antitumor preparation |
| 03/28/2013 | US20130078307 Nicotine-containing pharmaceutical composition |
| 03/28/2013 | US20130078306 Medicaments containing vardenafil hydrochloride trihydrate |
| 03/28/2013 | US20130078305 Pharmaceutical Compositions For The Coordinated Delivery Of NSAIDs |
| 03/28/2013 | US20130078304 Controlled release formulation for treating sleep disorders |
| 03/28/2013 | US20130078303 Soft-gelatin capsule formulation |
| 03/28/2013 | US20130078299 Transdermal Patches Having Ionized Beam Crosslinked Polymers and Improved Release Characteristics |
| 03/28/2013 | US20130078290 Gastroretentive Dosage Forms Of GABA Analogs |
| 03/28/2013 | US20130078288 Method of Treating Cancer |
| 03/28/2013 | US20130078287 Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist |
| 03/28/2013 | US20130078286 Drug delivery system |
| 03/28/2013 | US20130078284 Pharmaceutical formulations |
| 03/28/2013 | US20130078279 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
| 03/28/2013 | US20130078272 Fungicidal compounds and methods of their use |
| 03/28/2013 | US20130078266 Immunosuppression By Blocking T Cell Co-Stimulation Signal 2 (B7/CD28 Interaction) |
| 03/28/2013 | US20130078260 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media |
| 03/28/2013 | US20130078256 Novel hiv reverse transcriptase inhibitors |
| 03/28/2013 | US20130078252 Combination treatments comprising c-met antagonists and b-raf antagonists |
| 03/28/2013 | US20130078233 Compositions and methods using same for treating amyloid-associated diseases |
| 03/28/2013 | US20130078228 Vitamin-containing nutrition infusion for administration through peripheral vein |
| 03/28/2013 | US20130078218 Hepatitis c therapies |
| 03/28/2013 | US20130078217 2'-chloroacetylenyl substituted nucleoside derivatives |
| 03/28/2013 | US20130078215 Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions |
| 03/28/2013 | US20130078214 Compounds for the Treatment of Hepatitis C |
| 03/28/2013 | US20130078213 Thrombopoietin mimetics |
| 03/28/2013 | US20130078210 Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles |
| 03/28/2013 | US20130078209 Compositions and methods for treating conditions of compromised skin barrier function |
| 03/28/2013 | US20130078194 Compositions for dental treatment comprising lipoteichoic acids or parts thereof like mono- or polyglycerphosphates |
| 03/28/2013 | US20130074834 Pharmaceutical Combinations |
| 03/28/2013 | DE102011114986A1 Sprühsystem Spray system |
| 03/28/2013 | CA2858033A1 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof |
| 03/28/2013 | CA2851492A1 Ophthalmic gel compositions |
| 03/28/2013 | CA2850558A1 Beta-lactam compounds for treating diabetes |
| 03/28/2013 | CA2849732A1 Buffered upper gi absorption promoter |
| 03/28/2013 | CA2849731A1 Acetaminophen conjugates, compositions and methods of use thereof |
| 03/28/2013 | CA2849726A1 Amide compounds, compositions and applications thereof |
| 03/28/2013 | CA2849711A1 Compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants), application of pharmaceutical substance, pharmaceutical and parapharmaceuticalformulation (variants), method of preparation of pharmaceutical compositions |
| 03/28/2013 | CA2849708A1 Romidepsin and 5 - azacitidine for use in treating lymphoma |
| 03/28/2013 | CA2849702A1 Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| 03/28/2013 | CA2849505A1 Sodium channel blockers reduce glucagon secretion |
| 03/28/2013 | CA2849475A1 Novel betulinic acid derivatives with antiviral activity |
| 03/28/2013 | CA2849442A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | CA2849369A1 Compositions and methods related to deoxycholic acid and its polymorphs |
| 03/28/2013 | CA2849366A1 Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| 03/28/2013 | CA2849357A1 Acyclic cyanoethylpyrazoles as janus kinase inhibitors |
| 03/28/2013 | CA2849345A1 Substituted imidazopyridazines |
| 03/28/2013 | CA2849343A1 Use of strigolactones and strigolactone analogs for treating proliferative conditions |
| 03/28/2013 | CA2849340A1 Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
| 03/28/2013 | CA2849309A1 Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications |
| 03/28/2013 | CA2849279A1 Interomone compositions and their use to modify behavior in different vertebrate species |
| 03/28/2013 | CA2849273A1 Antisense modulation of gcgr expression |
| 03/28/2013 | CA2849255A1 A composition and method for treating an autoimmune disease |
| 03/28/2013 | CA2849189A1 Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| 03/28/2013 | CA2849176A1 Fsh receptor antagonists |
| 03/28/2013 | CA2849169A1 Pyrazole carboxamides as janus kinase inhibitors |
| 03/28/2013 | CA2849168A1 Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
| 03/28/2013 | CA2849111A1 Fsh receptor antagonists |
| 03/28/2013 | CA2849109A1 N-piperidin-4-yl derivatives |
| 03/28/2013 | CA2849078A1 Method and composition for treating pain |
| 03/28/2013 | CA2849073A1 Modified creatine compounds |
| 03/28/2013 | CA2849055A1 N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
| 03/28/2013 | CA2849039A1 Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| 03/28/2013 | CA2849037A1 Microbubble complexes and methods of use |
| 03/28/2013 | CA2848929A1 Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c |
| 03/28/2013 | CA2848512A1 Method for treating osteoporosis |